5 Tips about Clinical effectiveness of ABBV-744 in AML patients You Can Use Today
In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will acquire treatment until disorder progression or even the members are unable to tolerate the study drugs.- "Our study exposed the vital position with the KLF16/MYC regulatory axis in modulating tumor expan